you are here: HomeNewsBiocon
biocon
Jump to
1507 Results Found
  • Stimulus package can help biotech sector become self-reliant: Kiran Mazumdar-Shaw May 17, 2020 07:25 AM IST

    Stimulus package can help biotech sector become self-reliant: Kiran Mazumdar-Shaw

    Mazumdar-Shaw said that the world is waiting for a vaccine for COVID-19 but till the time it is developed, there is a need to conduct tests and build a treatment regime to save lives.

  • Biocon Consolidated March 2020 Net Sales at Rs 1,581.00 crore, up 3.41% Y-o-Y May 15, 2020 09:35 AM IST

    Biocon Consolidated March 2020 Net Sales at Rs 1,581.00 crore, up 3.41% Y-o-Y

  • Biocon share price falls 3% post Q4 numbers May 15, 2020 09:31 AM IST

    Biocon share price falls 3% post Q4 numbers

    Revenue from operations was up 3 percent at Rs 1,581 crore versus Rs 1,528.8 crore year-on-year.

  • Biocon Q4 profit declines 42% to Rs 123 crore May 15, 2020 08:27 AM IST

    Biocon Q4 profit declines 42% to Rs 123 crore

    Revenue was up 3 percent to Rs 1,581 crore versus Rs 1,529 crore.

  • Biocon share price rises on GMP compliance May 12, 2020 09:53 AM IST

    Biocon share price rises on GMP compliance

    The inspection was inspected by the regulatory agency between January 20 and 23, 2020.

  • Biocon gets establishment inspection report from USFDA for Bengaluru plant May 08, 2020 01:11 PM IST

    Biocon gets establishment inspection report from USFDA for Bengaluru plant

    The company has received the EIR from the US Food and Drug Administration (USFDA) for the pre-approval and good manufacturing practice inspection of its small molecules active pharmaceutical ingredient (API) manufacturing facility at Biocon Park SEZ, Bengaluru, it said in a filing to BSE.

  • Biocon share price up 2% on receiving EIR from USFDA May 08, 2020 10:06 AM IST

    Biocon share price up 2% on receiving EIR from USFDA

    The inspection was conducted between January 20 and January 24, 2020.

  • COVID-19 will reboot world into virtual reality: Kiran Mazumdar-Shaw Apr 18, 2020 08:45 PM IST

    COVID-19 will reboot world into virtual reality: Kiran Mazumdar-Shaw

    "The seismic events unleashed by the COVID-19 pandemic will have a powerful impact on the world we live in, changing it in ways we had never imagined were possible. The economic damage is likely to be unprecedented," Mazumdar-Shaw said.

  • Biocon gains 5% on EIR from USFDA for 2 units; MFs, LIC raise stake in March quarter Apr 16, 2020 12:33 PM IST

    Biocon gains 5% on EIR from USFDA for 2 units; MFs, LIC raise stake in March quarter

    LIC also raised its stake to 1.55 percent at the end of March quarter, from 1.16 percent in previous quarter. However FPIs cut their stake in the company to 14.98 percent during the quarter, from 16.09 percent QoQ.

  • Biocon Biologics receives EIR from USFDA for 2 manufacturing facilities Apr 16, 2020 10:15 AM IST

    Biocon Biologics receives EIR from USFDA for 2 manufacturing facilities

    The inspection was conducted between September 10 and September 19, 2019, a company spokesperson said, adding, Biocon Biologics has responded to the regulator on the eight observations from this inspection, in October last year.

  • Covid-19| Can supply cancer and diabetes medicines at reasonable price, Biocon tells West Bengal government Apr 11, 2020 04:25 PM IST

    Covid-19| Can supply cancer and diabetes medicines at reasonable price, Biocon tells West Bengal government

    The biopharmaceutical major, led by Kiran Mazumdar Shaw, has written to the West Bengal government offering medicines, including "additional support" services, to assist the state officials.

  • SC judgment on free COVID-19 testing by private labs not practical, says Biocon's Mazumdar Shaw Apr 09, 2020 12:28 PM IST

    SC judgment on free COVID-19 testing by private labs not practical, says Biocon's Mazumdar Shaw

    Mazumdar-Shaw said testing by private labs will plummet, since they are conducting the tests at an upfront cost.

  • After COVID-19, there will be huge effort to lower healthcare costs: Biocon's Kiran Mazumdar-Shaw Apr 01, 2020 01:18 PM IST

    After COVID-19, there will be huge effort to lower healthcare costs: Biocon's Kiran Mazumdar-Shaw

    COVID-19 crisis has shown us that we have to focus on these very important healthcare areas. Infectious diseases have been neglected and ignored for too long, Mazumdar-Shaw pointed out.

  • Biocon's insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA Apr 01, 2020 10:30 AM IST

    Biocon's insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA

    In a regulatory filing the company said, Biocon Sdn Bhd, a subsidiary of Biocon Ltd has received the EIR from the USFDA for the Pre-Approval Inspection (PAI) of its insulin manufacturing facility in Malaysia, for Insulin Glargine.

  • Biocon share price rises nearly 5% on EIR for Malaysia facility Apr 01, 2020 09:50 AM IST

    Biocon share price rises nearly 5% on EIR for Malaysia facility

    Company's subsidiary Biocon Sdn Bhd has received the establishment inspection report (EIR) from the US FDA for the pre-approval inspection of the Malaysia facility.

  • Biocon, Biocon Biologics activate business continuity plans across functions in wake of COVID-19 Mar 27, 2020 04:23 PM IST

    Biocon, Biocon Biologics activate business continuity plans across functions in wake of COVID-19

    Biocon will continue to operate essential pharmaceutical manufacturing in full compliance with government requirements, it added.

  • Public health system in India not robust: Kiran Mazumdar Shaw Mar 23, 2020 02:55 PM IST

    Public health system in India not robust: Kiran Mazumdar Shaw

    Shaw said that COVID-19 is still under control in India, but we need to be very careful.

  • Biocon share price rises 3% on EIR from USFDA Mar 20, 2020 09:30 AM IST

    Biocon share price rises 3% on EIR from USFDA

    The inspection was conducted between February 20 to 26, 2020 and EIR has been closed with a “VAI” classification.

  • Biocon share price falls 2% on observations from USFDA Feb 27, 2020 09:46 AM IST

    Biocon share price falls 2% on observations from USFDA

    The USFDA conducted a post-approval and GMP inspection of the small-molecule API manufacturing facility in the Biocon Campus in Bengaluru between February 20 and 26.

  • Biocon shares decline 6% after USFDA observations for Bengaluru unit Feb 25, 2020 11:54 AM IST

    Biocon shares decline 6% after USFDA observations for Bengaluru unit

    The USFDA had issued a Form 483 with five observations for Bengaluru unit.

  • Need to worry about impact if spread of coronavirus continues: Kiran Mazumdar Shaw Feb 20, 2020 04:49 PM IST

    Need to worry about impact if spread of coronavirus continues: Kiran Mazumdar Shaw

    When asked about the situation with regards to supply and raw material prices, Mazumdar Shaw said, "If this continues beyond six months, we do have to worry about the impact. For now, we are okay."

  • Primary healthcare can play key role in combating outbreaks like coronavirus: Kiran Mazumdar-Shaw Feb 19, 2020 09:40 PM IST

    Primary healthcare can play key role in combating outbreaks like coronavirus: Kiran Mazumdar-Shaw

    Reiterating on the importance of primary healthcare, she said, "It is the starting point for looking at how to basically diagnose early, how to basically create awareness, how to basically immunise people in a community."

  • Biocon Standalone December 2019 Net Sales at Rs 501.30 crore, down 32.23% Y-o-Y Jan 28, 2020 12:15 PM IST

    Biocon Standalone December 2019 Net Sales at Rs 501.30 crore, down 32.23% Y-o-Y

  • Biocon Consolidated December 2019 Net Sales at Rs 1,748.10 crore, up 13.45% Y-o-Y Jan 28, 2020 12:08 PM IST

    Biocon Consolidated December 2019 Net Sales at Rs 1,748.10 crore, up 13.45% Y-o-Y

  • New launches to help Biocon Biologics reach $1 bn revenue target by FY22: Christiane Hamacher Jan 27, 2020 09:23 PM IST

    New launches to help Biocon Biologics reach $1 bn revenue target by FY22: Christiane Hamacher

    The biologics segment grew 50 percent year-on-year (YoY) in nine-month period to Rs 1594 crores, led primarily by contributions from Pegfilgrastim and Trastuzumab in US market.

Sections